ERBB2 and breast cancer: The median OS was 22 months (95% CI, 16 to 30) for all patients (Supplemental Fig. 4), 41 months (95% CI, 23 to 64) for patients with BC HER2-positive status and 14 months (95% CI, 11 to 23) for HER2-negative tumors (Supplemental Fig. 6).